Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01782963
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 4
- Registration Number
- NCT01779167
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
- Conditions
- Adult Myelodysplastic SyndromeAnemiaChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 52
- Registration Number
- NCT01772420
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
- Conditions
- Multiple MyelomaNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT01755975
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Saint Francis/Mount Sinai Regional Cancer Center, Hartford, Connecticut, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
- Conditions
- Lymphoid LeukemiaSmall Lymphocytic LymphomaLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 36
- Registration Number
- NCT01754857
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Lenalidomide After Allo Transplant
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT01750762
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Ipilimumab and Lenalidomide in Advanced Cancer
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 101
- Registration Number
- NCT01750983
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT01749969
- Locations
- 🇺🇸
Investigational Site Number 840004, San Francisco, California, United States
🇺🇸Investigational Site Number 840003, Columbus, Ohio, United States
🇺🇸Investigational Site Number 840001, Tampa, Florida, United States
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
- Conditions
- Non-Hodgkins LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaB-cell LymphomasWaldenstrom's MacroglobulinemiaMarginal Zone LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01744912
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 37
- Registration Number
- NCT01743859
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.